Skip to main content
SpringerLink
Log in

Bone Health Management

  • Chapter
  • First Online:
Urologic Oncology

  • 788 Accesses

Abstract

Bone integrity in men living with prostate cancer can be jeopardized in different ways. In men affected with nonmetastatic prostate cancer, androgen deprivation therapy decreases bone mass density resulting in a higher incidence of osteoporosis and osteoporotic fractures. For patients with metastatic prostate cancer, the high frequency of bone metastases leads to skeletal-related events and affects patients’ quality of life and increases mortality. Bone-targeted agents, bisphosphonates and denosumab, proved their efficacy in reducing these deleterious outcomes, which had led to their approval in different stages of prostate cancer. This chapter focuses on the different parameters that regulate bone metabolism, androgen deprivation therapy-related bone loss, and on the optimal management of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  Google Scholar 

  2. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.

    PubMed  Google Scholar 

  3. James ND, Rush H, Clarke N, Attard G, Cook A, Dearnaley D. 611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476). Ann Oncol. 2020;31:S509.

    Google Scholar 

  4. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.

    PubMed  Google Scholar 

  5. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–6.

    CAS  PubMed  Google Scholar 

  6. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Huggins C, Hodges CV. Studies on prostatic cancer. I. the effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–40.

    CAS  PubMed  Google Scholar 

  8. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.

    CAS  PubMed  Google Scholar 

  9. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87(8):3656–61.

    CAS  PubMed  Google Scholar 

  10. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.

    CAS  PubMed  Google Scholar 

  11. Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014;45(3):370–81.

    CAS  PubMed  Google Scholar 

  12. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–7.

    PubMed  Google Scholar 

  13. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16(3):229–38.

    CAS  PubMed  Google Scholar 

  14. Hendrickx G, Boudin E, Van Hul W. A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol. 2015;11(8):462–74.

    PubMed  Google Scholar 

  15. Callaway DA, Jiang JX. Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab. 2015;33(4):359–70.

    CAS  PubMed  Google Scholar 

  16. Jilka RL, O'Brien CA, Roberson PK, Bonewald LF, Weinstein RS, Manolagas SC. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age. J Bone Miner Res. 2014;29(1):103–17.

    CAS  PubMed  Google Scholar 

  17. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev. 2004;25(3):389–425.

    CAS  PubMed  Google Scholar 

  18. Chen JF, Lin PW, Tsai YR, Yang YC, Kang HY. Androgens and androgen receptor actions on bone health and disease: from androgen deficiency to androgen therapy. Cell. 2019;8(11).

    Google Scholar 

  19. Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, et al. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology. 2001;142(9):3800–8.

    CAS  PubMed  Google Scholar 

  20. Manolagas SC, O'Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9(12):699–712.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Bienz M, Saad F. Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review. Bonekey Rep. 2015;4:716.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Eisman JA, Bouillon R. Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice. Bonekey Rep. 2014;3:499.

    PubMed  PubMed Central  Google Scholar 

  23. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185–94.

    PubMed  Google Scholar 

  25. Leslie WD, Tsang JF, Caetano PA, Lix LM, Manitoba Bone Density P. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab. 2007;92(1):77–81.

    CAS  PubMed  Google Scholar 

  26. Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD. Low bone mineral density and fracture burden in postmenopausal women. CMAJ. 2007;177(6):575–80.

    PubMed  PubMed Central  Google Scholar 

  27. Marques A, Ferreira RJ, Santos E, Loza E, Carmona L, da Silva JA. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1958–67.

    PubMed  Google Scholar 

  28. Akhtar M, Haider A, Rashid S, Al-Nabet A. Paget’s “seed and soil” theory of cancer metastasis: an idea whose time has come. Adv Anat Pathol. 2019;26(1):69–74.

    CAS  PubMed  Google Scholar 

  29. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem. 1986;261(27):12665–74.

    CAS  PubMed  Google Scholar 

  30. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–64.

    CAS  PubMed  Google Scholar 

  31. Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis. 2003;20(2):171–80.

    CAS  PubMed  Google Scholar 

  32. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994;54(9):2372–7.

    CAS  PubMed  Google Scholar 

  33. Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497–506.

    CAS  PubMed  Google Scholar 

  34. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    CAS  PubMed  Google Scholar 

  35. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.

    CAS  PubMed  Google Scholar 

  36. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92.

    CAS  PubMed  Google Scholar 

  38. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.

    CAS  PubMed  Google Scholar 

  39. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27(11):3239–49.

    CAS  PubMed  Google Scholar 

  41. Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of sost/sclerostin. J Bone Miner Res. 2016;31(10):1791–802.

    CAS  PubMed  Google Scholar 

  42. Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology. 2006;147(7):3613–22.

    CAS  PubMed  Google Scholar 

  43. Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. Calcif Tissue Int. 2018;102(2):251–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410–7.

    CAS  PubMed  Google Scholar 

  45. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157(2):439–44.

    CAS  PubMed  Google Scholar 

  46. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161(4):1219–22.

    CAS  PubMed  Google Scholar 

  47. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86(6):2787–91.

    CAS  PubMed  Google Scholar 

  48. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897–903.

    CAS  PubMed  Google Scholar 

  49. Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, et al. Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care – Cancer Care Ontario Clinical Practice Guideline. Clin Oncol (R Coll Radiol). 2017;29(6):348–55.

    CAS  Google Scholar 

  50. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, Group EGW. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25 Suppl 3:iii124–37.

    CAS  PubMed  Google Scholar 

  51. Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. J Clin Oncol. 2020;38(15):1736–43.

    PubMed  Google Scholar 

  52. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–66.

    CAS  PubMed  Google Scholar 

  53. Cormie P, Galvao DA, Spry N, Joseph D, Chee R, Taaffe DR, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115(2):256–66.

    PubMed  Google Scholar 

  54. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045–52.

    PubMed  Google Scholar 

  55. Winters-Stone KM, Dobek JC, Bennett JA, Maddalozzo GF, Ryan CW, Beer TM. Skeletal response to resistance and impact training in prostate cancer survivors. Med Sci Sports Exerc. 2014;46(8):1482–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Uth J, Hornstrup T, Christensen JF, Christensen KB, Jorgensen NR, Schmidt JF, et al. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. Osteoporos Int. 2016;27(4):1507–18.

    CAS  PubMed  Google Scholar 

  57. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97(12):2692–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88(6):2095–105.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Fleisch H. Pharmacokinetics. Biphosphonates in bone disease: from the laboratory to the patient, 1993.

    Google Scholar 

  60. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Ding H, Yang L, Du W, Teng Y, Fu SJ, Tao Y, et al. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2013;14(5):3337–43.

    PubMed  Google Scholar 

  62. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.

    CAS  PubMed  Google Scholar 

  63. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.

    CAS  PubMed  Google Scholar 

  65. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, et al. Adding celecoxib with or without Zoledronic acid for hormone-naive prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform. Randomized Controlled Trial J Clin Oncol. 2017;35(14):1530–41.

    CAS  PubMed  Google Scholar 

  67. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014;32(11):1143–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Clemons M, Ong M, Stober C, Ernst S, Booth C, Canil C, et al. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer. 2021;142:132–40.

    CAS  PubMed  Google Scholar 

  69. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341–7.

    CAS  PubMed  Google Scholar 

  70. Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406.

    CAS  PubMed  Google Scholar 

  71. Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. Cancer Treat Rev. 2018;68:25–37.

    CAS  PubMed  Google Scholar 

  72. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, et al. Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015;68(4):570–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.

    PubMed  PubMed Central  Google Scholar 

  74. Radium-223-dichloride (Xofigo): Increased risk of death and fractures in a randomised clinical trial with Xofigo used in combination with abiraterone acetate and prednisolone/prednisone, 2017.

    Google Scholar 

  75. Tombal F LY, Saad F. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone; an interim safety analysis. ASCO; Chicago, IL, 2019.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division on Hematology Oncology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada

    Zineb Hamilou

  2. Department of Surgery, Division of Urology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada

    Fred Saad

Authors
  1. Zineb Hamilou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fred Saad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zineb Hamilou .

Editor information

Editors and Affiliations

  1. Urology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA

    Kelly L. Stratton

  2. Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Alicia K. Morgans

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hamilou, Z., Saad, F. (2022). Bone Health Management. In: Stratton, K.L., Morgans, A.K. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-89891-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-89891-5_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-89890-8

  • Online ISBN: 978-3-030-89891-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation